Previous 10 | Next 10 |
Mustang Bio (MBIO): Q1 GAAP EPS of -$0.19 in-line.As of March 31, 2021, Mustang’s cash and cash equivalents and restricted cash totaled $130.4 million, compared to $98.8 million as of December 31, 2020, an increase of $31.6 million year-to-date.Press release. For further details see:...
WORCESTER, Mass., May 14, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, soli...
WORCESTER, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, soli...
Mustang Bio ([[MBIO]] -0.7%) has made available updated data from its ongoing Phase 1/2 clinical trial of MB-106 for patients with relapsed or refractory B-cell non-Hodgkin lymphoma (“NHL”).Newly released data were included in an abstract released ahead of the upcoming European ...
Mustang Bio (MBIO) announces that the FDA has accepted its Investigational New Drug ((IND)) application to initiate a Phase 1/2 study to assess the safety, tolerability and efficacy of MB-106, a CD20-targeted CAR T therapy for relapsed or refractory CD20+ B-cell non-Hodgkin lymphoma (B-NHL) a...
Alfi (ALF) +35%.SemiLEDs Corporation (LEDS) +19%.Protagenic Therapeutics (PTIX) +18%.Party City Holdco (PRTY) +12% on Q1 results.BioNTech SE (BNTX) +9% on Q1 results.Aptorum Group Limited (APM) +8%.VYNE Therapeutics (VYNE) +8%.Inovio Pharmaceuticals (INO) +8% on positive data f...
The Phase 1/2 multicenter study to assess the safety, tolerability and efficacy of MB-106 in patients with relapsed or refractory CD20+ B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia is expected to begin enrolling patients in the third quarter of this year WORCESTER,...
WORCESTER, Mass., April 21, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, so...
Are These The Top Biotech Penny Stocks to Buy in April? The pandemic has shined a large spotlight on biotech penny stocks over the past twelve months. Every time a company announced a new treatment or vaccine for Covid, traders quickly jumped to buy the trend. As a result, many breakout...
Does Your List Of Robinhood Penny Stocks Have These On It? Penny stocks are some of the highest risk investment classes in the stock market today. Yet they remain sought after by day traders and investors alike. The short-term prospects entail high-flying shares, turning a big profit qu...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released Update Note on Enveric Biosciences Inc. (NASDAQ: ENVB). The update note includes information on the Enveric Bioscience’s ma...
WORCESTER, Mass., June 21, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficul...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...